PT - JOURNAL ARTICLE AU - Babs G Sibinga Mulder AU - J Sven D Mieog AU - Henricus J M Handgraaf AU - Arantza Farina Sarasqueta AU - Hans F A Vasen AU - Thomas P Potjer AU - Rutger-Jan Swijnenburg AU - Saskia A C Luelmo AU - Shirin Feshtali AU - Akin Inderson AU - Alexander L Vahrmeijer AU - Bert A Bonsing AU - Tom van Wezel AU - Hans Morreau TI - Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer AID - 10.1136/jclinpath-2016-203928 DP - 2017 Feb 01 TA - Journal of Clinical Pathology PG - 174--178 VI - 70 IP - 2 4099 - http://jcp.bmj.com/content/70/2/174.short 4100 - http://jcp.bmj.com/content/70/2/174.full SO - J Clin Pathol2017 Feb 01; 70 AB - To improve the diagnostic value of fine-needle aspiration (FNA)-derived material, we perform targeted next-generation sequencing (NGS) in patients with a suspect lesion of the pancreas. The NGS analysis can lead to a change in the treatment plan or supports inconclusive or uncertain cytology results. We describe the advantages of NGS using one particular patient with a recurrent pancreatic lesion 7 years after resection of a pancreatic ductal adenocarcinoma (PDAC). Our NGS analysis revealed the presence of a presumed second primary cancer in the pancreatic remnant, which led to a change in treatment: resection with curative intend instead of palliation. Additionally, NGS identified an unexpected germline CDKN2A 19-base pair deletion, which predisposed the patient to developing PDAC. Preoperative NGS analysis of FNA-derived DNA can help identify patients at risk for developing PDAC and define future therapeutic options.